

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s):	Zoltan Kiss	Examiner:	
Appn. No.:	10/582,391	Group Art Unit:	
Filing Date:	June 9, 2006	Confirmation No.:	
Title:	METHOD FOR IMPROVING INSULIN SENSITIVITY BY ADMINISTERING AN INHIBITOR OF ANTITRYPSIN	Customer No.:	25764
		Docket No.:	59496 - 336756

Commissioner for Patents
 P. O. Box 1450
 Alexandria, VA 22313-1450

I CERTIFY THAT THIS CORRESPONDENCE IS BEING ELECTRONICALLY
 TRANSMITTED TO THE U.S. PATENT AND TRADEMARK OFFICE ON
 DECEMBER 29, 2006.


 Amber Friend

INFORMATION DISCLOSURE STATEMENT

In compliance with the duty imposed by 37 C.F.R. 1.56, and in accordance with C.F.R. sections 1.97 *et seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application.


Consideration of each of the documents listed on the attached SB/08 form(s) is respectfully requested. The filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is construed to be, prior art or material to the patentability of the present application.

This Information Disclosure Statement is being filed before the receipt of an Office Action on the merits. No fee is believed to be necessary. However, should any fee be required, the Commissioner is authorized to charge our Deposit Account No. 06-0029 and is requested to notify us of the same.

Respectfully submitted,

FAEGRE & BENSON LLP

By:


 Tanya S. D'Souza, Reg. No. 56,948
 612/766-7835 Customer No.: 25764

Dated: December 29, 2006

fb us 1726342.01

Substitute for Form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/582,391
				Filing Date	December 9, 2004
				First Named Inventor	Zoltan Kiss
				Art Unit	
				Examiner Name	
(Use as many sheets as necessary)					
Sheet	1	of	4	Attorney Docket Number	59496 - 336756

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

"EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and initial
considered. Include copy of this form with next communication to applicant." Applicant's unique station designation number (optional): See Final Codes of
USPTO Patent Documents at www.uspto.gov or MPEP 904.04. Enter Office that issued the document by the two-letter code (WIPO Standard ST-3). For
Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by
the appropriate symbols as indicated on the document under WIPO Standard ST-16 if possible. "Applicant is to place a check mark here if English language
Translation is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	4	Attorney Docket Number	59496 - 336756
-------	---	----	---	------------------------	----------------

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue numbers), publisher, city and/or country where published.	T ²
	ZIMMET et al., "Global and societal implications of the diabetes epidemic," <i>Nature</i> 414, pp. 782-787, 2001		
	SALTIEL et al., "Insulin signaling and the regulation of glucose and lipid metabolism," <i>Nature</i> 414, pp. 799-806, 2001		
	BELL et al., "Diabetes mellitus and genetically programmed defects in β-cell function." <i>Nature</i> 414, pp. 788-791 2001		
	MATHIS et al., "β-cell death during progression to diabetes." <i>Nature</i> 414, pp. 792-798, 2001		
	SALTIEL, "New perspectives into the molecular pathogenesis and treatment of Type 2 diabetes," <i>Cell</i> 104, pp. 517-529, 2001		
	MOLLER, "New drug targets for Type 2 diabetes and the metabolic syndrome," <i>Nature</i> 414, pp. 821-827, 2001		
	BROWNLEE, "Biochemistry and molecular cell biology of diabetic complications," <i>Nature</i> 414, pp. 813-820, 2001		
	HO et al., "Antioxidants, NFκB activation, and diabetogenesis," <i>Proc. Soc. Exp. Biol. Med.</i> 222, pp. 205-213, 1999		
	BODEN et al., "FFA cause hepatic insulin resistance by inhibiting suppression of glycogenolysis," <i>Am. J. Physiol. Endocrinol. Metab.</i> 283, pp. E12-E19, 2001		
	YU et al., "Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase in Muscle," <i>J. Biol. Chem.</i> 277, pp. 50230-50236, 2002		
	MAEDLER et al., "Distinct effects of saturated and monounsaturated fatty acids on β-cell turnover and function," <i>Diabetes</i> 50, pp. 69-76, 2001		
	PRADHAN et al., "C-reactive protein, interleukin 6, and risk of developing Type 2 diabetes mellitus," <i>JAMA</i> , 286, pp. 327-334, 2001		
	THOMPSON et al., "Insulin modulation of acute-phase protein production in a human hepatoma cell line," <i>Cytokine</i> 3, pp. 619-626, 1991		
	CAMPOS et al., "Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes," <i>Mol. Cell. Biol.</i> 12, 1789-1797, 1992		
	GANROT et al., "Serum concentration of α ₂ -macroglobulin, haptoglobin and α ₁ -antitrypsin in diabetes mellitus," <i>Acta Endocrinologica</i> 55, pp. 537-544, 1967		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹Applicant's unique citation designation number (optional) ²Applicant is to place a check mark here if English language Translation is attached.

SEN TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/582,391
				Filing Date	July 14, 2006
				First Named Inventor	Zoltan Kiss
				Art Unit	
				Examiner Name	
(Use as many sheets as necessary)		Sheet 3 of 4		Attorney Docket Number 59496 - 336756	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue numbers), publisher, city and/or country where published.	T ²
	MCMILLAN	"Increased levels of acute-phase serum proteins in diabetes," <i>Metabolism</i> 38, pp. 1042-1046, 1989	
	SCHMIDT et al.	"Markers of inflammation and prediction of diabetes mellitus in adults," <i>The Lancet</i> 353, pp. 1649-1652, 1999	
	JANCIAUSKIENE	"Conformational properties of serine proteinase inhibitors (serpins) confer multiple pathophysiological roles," <i>Biochim. Biophys. Acta</i> 1535, pp. 221-235, 2001	
	WEWERS et al.	"Replacement therapy for alpha ₁ -antitrypsin deficiency associated with emphysema," <i>N. Engl. J. Med.</i> 316, pp. 1055-1062, 1987	
	PERRAUD et al.	"Proliferation of rat astrocytes, but not of oligodendrocytes, is stimulated in vitro by protease inhibitors," <i>Int. J. Devl. Neuroscience</i> 6, pp. 261-266, 1988	
	SHE et al.	"α ₁ -antitrypsin can increase insulin-induced mitogenesis in various fibroblast and epithelial cell lines," <i>FEBS Lett.</i> 473, pp. 33-36, 2000	
	DABBAGH et al.	"Alpha-1-antitrypsin stimulates fibroblast proliferation and procollagen production and activates classical MAP kinase signalling pathways," <i>J. Cell. Physiol.</i> 186, pp. 73-81, 2001	
	GRAZIADEI et al.	"The acute phase protein α ₁ -antitrypsin inhibits growth and proliferation of human early erythroid progenitor cells (burst-forming units-erythroid) and of human erythroleukemic cells (K562) in vitro by interfering with transferring iron uptake," <i>Blood</i> 83, pp. 260-268, 1994	
	YAVELOW et al.	"α ₁ -antitrypsin blocks the release of transforming growth factor-α from MCF-7 human breast cancer cells," <i>J. Clin. Endocrinol. Metab.</i> 82, pp. 745-752, 1997	
	OZEKI et al.	"α ₁ -antitrypsin and hepatic fibrosis," <i>Br. J. Exp. Path.</i> 70, pp. 143-152, 1989	
	GRAZIADEI	"Modulation of iron metabolism in monocytic THP-1 cells and cultured human monocytes by the acute-phase protein α ₁ -antitrypsin," <i>Exp. Hematol.</i> 26, pp. 1053-1060, 1998	
	JANCIAUSKIENE et al.	"An interaction between Gemfibrozil and alpha ₁ -antitrypsin," <i>J. Internal Med.</i> 236, pp. 357-360, 1994	
	JANCIAUSKIENE et al.	"The interaction of hydrophobic bile acids with the α ₁ -proteinase inhibitor," <i>FEBS Lett.</i> 343, pp. 141-145, 1994	
	JANCIAUSKIENE et al.	"In vitro complex formation between cholesterol and α ₁ -proteinase inhibitor," <i>FEBS Lett.</i> 316, pp. 269-272, 1993	

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Induce copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

SEN TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for Form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	10/582,391
				<i>Filing Date</i>	July 14, 2006
				<i>First Named Inventor</i>	Zoltan Kiss
				<i>Art Unit</i>	
				<i>Examiner Name</i>	
(Use as many sheets as necessary)					
Sheet	4	of	4	Attorney Docket Number	59496 - 336756

NON-PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if no action considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance.

¹ Applicant's unique creation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.